Alingasa, Relmar C.
HRN: 22-64-33 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/01/2023
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
03/01/2023
03/07/2023
IV
2-3ml
Q6
Oral Candidiasis
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes